Table 2.
Discrimination of disease activity measurements between patients on ADA versus PBO
| ABILITY-2 | TIPES | |||||
|---|---|---|---|---|---|---|
| Mean Δ from BL ADA (SD), N=82 | Mean Δ from BL PBO (SD), N=81 | SMD | Mean Δ from BL ADA (SD), N=19 | Mean Δ from BL PBO (SD), N=19 | SMD | |
| PGA, 0–100 mm VAS | −28.0 (26.0)* | −16.2 (24.5)† | −0.47 | −31.0 (23.3) | −5.9 (21.4) | −1.12 |
| Patient global pain, 0–100 mm VAS | −29.3 (24.6) | −17.0 (24.4)† | −0.50 | −21.9 (26.9) | −0.6 (17.5) | −0.93 |
| PhGA, 0–100 mm VAS | −32.7 (22.5) | −18.2 (22.9) | −0.64 | −19.8 (19.5) | −4.1 (16.4) | −0.87 |
| ASDAS-CRP, 0–10 cm VAS | −1.1 (1.1)‡ | −0.5 (0.9)§ | −0.63 | −1.5 (1.2) | −0.6 (0.8) | −0.89 |
| BASDAI, 0–10 cm VAS | −2.1 (2.3) | −1.0 (2.2)† | −0.50 | −1.9 (2.6) | −0.3 (1.5) | −0.73 |
| BASDAI #1 | −1.9 (2.6) | −1.0 (2.6) | −0.36 | −1.2 (3.6) | −0.5 (2.3) | −0.20 |
| BASDAI #2 | −1.2 (3.0) | −0.0 (2.4) | −0.42 | −1.7 (3.3) | −0.8 (2.3) | −0.33 |
| BASDAI #3 | −2.9 (2.9) | −1.7 (2.9) | −0.40 | −2.6 (3.5) | −0.0 (1.5) | −0.96 |
| BASDAI #4 | −2.7 (2.9) | −1.2 (2.7) | −0.54 | −1.8 (2.7) | −0.1 (2.8) | −0.62 |
| BASDAI #5 | −2.3 (2.8) | −1.1 (2.7) | −0.44 | −2.8 (3.3) | −0.7 (2.1) | −0.77 |
| BASDAI #6 | −1.8 (2.8) | −1.2 (2.7) | −0.21 | −1.2 (3.3) | 0.0 (2.2) | −0.43 |
| BASDAI mean #5 and #6 | −2.1 (2.6) | −1.2 (2.5) | −0.35 | −2.0 (3.1) | −0.3 (1.9) | −0.64 |
| SJC 76¶ | −3.6 (4.3) | −3.1 (5.6) | −0.10 | −2.5 (4.1) | −0.4 (1.8) | −0.67 |
| TJC 78** | −6.0 (8.7) | −1.8 (8.4) | −0.50 | −1.8 (9.2) | 1.7 (6.5) | −0.45 |
| CRP (mg/L) | −5.8 (18.7)* | −2.9 (11.0)† | −0.18 | −5.7 (12.4) | 4.0 (22.9) | −0.53 |
Observed data.
*N=81.
†N=80.
‡N=80. §N=77.
¶In TIPES, SJC was 0–66 joints.
**In TIPES, TJC was 0–68 joints and patient global pain was derived from the mean of BASDAI #3 and #4.
ADA, adalimumab; ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score based on C-reactive protein; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BL, baseline; CRP, C-reactive protein; PBO, placebo; PGA, patient global assessment; PhGA, physician global assessment; SJC, swollen joint count; SMD, standardised mean difference; TIPES, Tnf Inhibition in PEripheral SpondyloArthritis; TJC, tender joint count; VAS, visual analogue scale; Δ, change.